July 14, 2021 — Performing the first cardiac scan on their new photon-counting detector computed tomography (CT) scanner was a once-in-a-career moment for Joel (J.G.) Fletcher, M.D., and Cynthia McCollough, Ph.D. The medical and scientific directors, respectively, of the

June 13, 2021 — Medtronic announced clinical trial results from the STROKE AF trial demonstrating the superiority of the Reveal Linq Insertable Cardiac Monitor (ICM) to detect abnormal heartbeats, otherwise known as atrial fibrillation (AF), in both large and small vessel stroke patients compared to standard of care.

July 13, 2021 — East End Medical announced it received U.S. Food and Drug Administration (FDA) clearance for the company's SafeCross Transseptal Radiofrequency (RF) Puncture and Steerable Balloon Introducer System.

July 13, 2021 — Researchers at Johns Hopkins Medicine have shown that speckle-tracking strain echocardiograms may predict which patients with COVID-19 are most at risk of developing atrial fibrillation (AF).

July 13, 2021 — In a recent blog, the American Society of Nuclear Cardiology (ASNC) reported that Humana, one of the largest commercial payers in the U.S., has reversed its Fusion policy, which restricted payment for certain PET/CT exams on the grounds that they were “experimental/investiga

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). Abbott announced the same day it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.

Medtronic announced in June it was stopping the sale and distribution of the Medtronic Heartware HVAD left ventricular assist device (LVAD). On June 3, the company notified physicians to cease new implants of the HVAD System and transition to an alternative means of durable mechanical circulatory support. Its primary competitor in the LVAD market, Abbott, also announced it has the capacity to meet increased demand for LVADs as Medtronic leaves the market.
The Xeltis synthetic polymer restorative pulmonary valve is implanted surgically and acts as a scaffold for the patient's own cells to proliferate. The valve and conduit then bioresorbs over time, leaving behind a new valve made from the patient's own cells. The hope is this will reduce or eliminate the need for numerous repeat surgeries as a pediatric patient grows.

July 8, 2021 – Xeltis announced it started the first pivotal trial for a synthetic polymer restorative pulmonary valve, the global, FDA-approved Xplore2/Pivotal study. Following implantation, the valves evolve into fully functioning, natural heart valves through colonization by the patient’s own tissue.

July 7, 2021 – Robocath, a company that designs, develops and commercializes cath lab robotic solutions to treat cardiovascular diseases, and Rennes University Hospital, announced the launch of a co-development research program using robotics to improve treatment for stroke victims.

July 2, 2021 — Philips has participated in an important research project to develop a magnetic resonance (MR) imaging technique [1,2] that could potentially revolutionize the use of MR imaging in cardiology.

Subscribe to
© Copyright Wainscot Media. All Rights Reserved.
Subscribe Now